Bococizumab is a novel anti-PCSK9 antibody specifically developed to address hypercholesterolemia. Such therapeutic agent interacts with the PCSK9 protein, a essential regulator of cholesterol amounts. By neutralizing https://www.targetmol.com/compound/bococizumab